NCT02231125

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,600 (estimated)
• Sponsor: Chen Xiangmei · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

-IgA nephropathy is the most common primary glomerular disease in China, Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating IgA nephropathy in large scale samples with long time take.

Detailed description

The test has not been completed .

Conditions

• IgA Nephropathy

Interventions

Type	Name	Description
DRUG	Losartan	Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
DRUG	Abelmoschus manihot	Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.

Timeline

• Start date: 2014-09-01
• Primary completion: 2016-07-01
• Completion: 2017-12-01
• First posted: 2014-09-04
• Last updated: 2016-07-06

Locations

88 sites across 1 country: China